Literature DB >> 17931063

Antibacterial activity of propolis against MRSA and synergism with topical mupirocin.

Yusuf Onlen1, Nizami Duran, Esin Atik, Lutfu Savas, Enes Altug, Selvinaz Yakan, Ozkan Aslantas.   

Abstract

OBJECTIVES: The aim of the present study was to investigate the activity of the propolis and its combinations with mupirocin against methicillin-resistant Staphylococcus aureus (MRSA) in nasal carriage.
METHODS: This study was carried out between June and August 2005. To infect nares of the rabbits, MRSA (ATCC 33591) strain was used. Minimum inhibitory concentration was determined according to National Committee for Clinical Laboratory Standards. Each inoculum was prepared in the same medium at a density adjusted to a 0.5 McFarland turbidity standard (10(5) colony-forming units [cfu]/mL) and diluted 1:100 for the broth microdilution procedure. Ten microliters (10 microL) (10(5) cfu/mL) of the bacterial suspension containing approximately 1000 cfu of MRSA was administered with sterile microsyringe through both nostrils of each rabbit. Ninety-six (96) hours after inoculation, the presence of infection was confirmed by using bacterial cultures. Twenty-six young New Zealand rabbits were randomly divided into 4 groups. Each treatment group (1, 2, and 3) included 7 rabbits and control group (group 4) included 5 rabbits. Group 1 was treated with topical mupirocin + ethanolic extract of propolis drops, group 2 received topical mupirocin, group 3 was administered ethanolic extract of propolis drops, and the control group (group 4) was only treated with phosphate-buffered solution drops for 7 days. At the end of study, nasal cultures and smears were obtained for bacterial count and cytologic examination.
RESULTS: The colony numbers of bacteria in group 1 were determined to be significantly lower than in group 2 (p = 0.0001), group 3 (p = 0.0001), and group 4 (p = 0.0001). The mean bacterial cell counts of groups 1-4 were 360.2 +/- 52.4 cfu/mL, 4120.6 +/- 860.4 cfu/mL, 5980.8 +/- 1240.6 cfu/mL, and 11500.0 +/- 2568.4 cfu/mL, respectively. Mupirocin + propolis administration (group 1) resulted in a significant reduction in the polymorphonuclear leukocyte (PMNL) count in the mucous membranes of rabbits compared with the other treatment groups (p < 0.05).
CONCLUSIONS: Propolis addition to mupirocin regimen was found to result in more profound reduction in bacterial cell count and inflammatory response compared with the rest of the treatment modalities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17931063     DOI: 10.1089/acm.2007.7021

Source DB:  PubMed          Journal:  J Altern Complement Med        ISSN: 1075-5535            Impact factor:   2.579


  11 in total

1.  GC-MS analysis and antileishmanial activities of two Turkish propolis types.

Authors:  Nizami Duran; Mustafa Muz; Gulnaz Culha; Gulay Duran; Burcin Ozer
Journal:  Parasitol Res       Date:  2010-09-15       Impact factor: 2.289

Review 2.  An Overview of the Evidence and Mechanism of Drug-Herb Interactions Between Propolis and Pharmaceutical Drugs.

Authors:  Sanowar Hossain; Muhammad Yousaf; Yang Liu; Dennis Chang; Xian Zhou
Journal:  Front Pharmacol       Date:  2022-04-04       Impact factor: 5.988

3.  Antiviral Activity of Hatay Propolis Against Replication of Herpes Simplex Virus Type 1 and Type 2.

Authors:  Ayse Yildirim; Gulay Gulbol Duran; Nizami Duran; Kemal Jenedi; Behiye Sezgin Bolgul; Meral Miraloglu; Mustafa Muz
Journal:  Med Sci Monit       Date:  2016-02-09

4.  Extract of Propolis on Resin-Modified Glass Ionomer Cement: Effect on Mechanical and Antimicrobial Properties and Dentin Bonding Strength.

Authors:  Narges Panahandeh; Fatemeh Adinehlou; Seyedeh Mahsa Sheikh-Al-Eslamian; Hassan Torabzadeh
Journal:  Int J Biomater       Date:  2021-04-12

5.  Analysis of antimicrobial activity of Karnataka propolis against oral pathogens - An in vitro study.

Authors:  Sowmya Srinivas; Anil Kumar Gujjari; Mruthunjaya Kenganora; Sushma Rudraswamy; M B Ravi; S Manjula
Journal:  J Oral Maxillofac Pathol       Date:  2022-01-11

6.  In Vitro Antimicrobial Activity of Ethanolic Extract of Polish Propolis against Biofilm Forming Staphylococcus epidermidis Strains.

Authors:  Robert D Wojtyczka; Małgorzata Kępa; Danuta Idzik; Robert Kubina; Agata Kabała-Dzik; Arkadiusz Dziedzic; Tomasz J Wąsik
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-10       Impact factor: 2.629

7.  Antimicrobial and antiproliferative activities of stingless bee Melipona scutellaris geopropolis.

Authors:  Marcos Guilherme da Cunha; Marcelo Franchin; Lívia Câmara de Carvalho Galvão; Ana Lúcia Tasca Góis de Ruiz; João Ernesto de Carvalho; Masarahu Ikegaki; Severino Matias de Alencar; Hyun Koo; Pedro Luiz Rosalen
Journal:  BMC Complement Altern Med       Date:  2013-01-28       Impact factor: 3.659

8.  Synergistic effects of honey and propolis toward drug multi-resistant Staphylococcus aureus, Escherichia coli and Candida albicans isolates in single and polymicrobial cultures.

Authors:  Noori Al-Waili; Ahmad Al-Ghamdi; Mohammad Javed Ansari; Y Al-Attal; Khelod Salom
Journal:  Int J Med Sci       Date:  2012-10-26       Impact factor: 3.738

9.  Evaluation of the in vitro antimicrobial activity of an ethanol extract of Brazilian classified propolis on strains of Staphylococcus aureus.

Authors:  Lucila Coelho Pamplona-Zomenhan; Beatriz Coelho Pamplona; Cely Barreto da Silva; Maria Cristina Marcucci; Lycia Mara Jenné Mimica
Journal:  Braz J Microbiol       Date:  2011-12-01       Impact factor: 2.476

10.  The Anti-Staphylococcal Potential of Ethanolic Polish Propolis Extracts.

Authors:  Katarzyna Grecka; Piotr M Kuś; Piotr Okińczyc; Randy W Worobo; Justyna Walkusz; Piotr Szweda
Journal:  Molecules       Date:  2019-05-03       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.